Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:27 12/05/2026 BST			5-day change	1st Jan Change
112.37 ^USD	+0.98%		-0.69%	+6.75%

05-12	Merck highlights new long-term data and advancements across broad oncology portfolio and pipeline research at Asco 2026	RE
05-11	Erasca Teams With Merck on AURORAS-1 Cancer Study	MT

Merck CEO Pay Falls 10% in 2025 Due to Lower Stock, Option Awards

Published on 04/08/2026 at 10:28 pm BST

Dow Jones

MERCK & CO., INC.

+0.98%

By Katherine Hamilton

Merck Chief Executive Robert Davis's total compensation fell 10% in 2025, mostly due to lower stock and option awards.

The executive was awarded a total compensation of $20.8 million in 2025, down from $23.2 million the year before, according to a Wednesday filing with the Securities and Exchange Commission.

His stock awards declined by $1 million to $12.1 million, and his option awards fell by $1.3 million to $3.4 million. His non-equity incentive plan compensation also declined by less than half a million dollars.

Davis's base salary increased to $1.65 million in 2025 from $1.62 million in 2024.

Chief Financial Officer Caroline Litchfield saw her total compensation remain flat at roughly $7.5 million.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

04-08-26 1727ET

Latest news about Merck & Co., Inc.

05-12	Merck highlights new long-term data and advancements across broad oncology portfolio and pipeline research at Asco 2026	RE
05-11	Erasca Teams With Merck on AURORAS-1 Cancer Study	MT
05-11	Erasca, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA (Pembrolizumab)	CI
05-07	The Rally Spreads
05-05	Merck Completes Terns Pharmaceuticals Acquisition	MT
05-04	Global pharma companies that have publicly announced Trump drug pricing agreements	RE
05-01	Goldman Sachs Adjusts Merck Price Target to $137 From $133	MT
05-01	Wells Fargo Adjusts Merck Price Target to $145 From $150	MT
05-01	Big Pharma M&A set for mega year as patent expiries drive deal urgency	RE
05-01	Morgan Stanley Raises Price Target on Merck to $112 From $109, Keeps Equalweight Rating	MT
05-01	Moderna first-quarter revenue jumps on strong overseas COVID vaccine sales	RE
04-30	S&P 500, Nasdaq on course for best month since 2020 despite Middle East risks	RE
04-30	Wall St set to climb at open as earnings optimism overshadows oil woes	RE
04-30	Wall St futures climb as investors balance earnings optimism against oil woes	RE
04-30	Merck beats quarterly sales expectations as Keytruda fuels growth	RE

Robert Davis

Mr. Robert M. Davis is an Independent Director at Duke Energy Corp., a President at Merck & Co., Inc. and a Chairman at Gambro AB. He is on the Board of Directors at Duke Energy Corp., AdvaMedDx, Project HOPE-The-People-To-People HealthFoundation, Inc. and Rush University Medical Center. Mr. Davis was previously employed as a Chief Financial Officer & Vice President by Baxter Healthcare Corp., a VP & President-Medical Products Business by Baxter International, Inc., and a Director-Corporate Financial Planning by Eli Lilly & Co. He also served on the board at C. R. Bard, Inc. (New Jersey). He received his undergraduate degree from Miami University, a graduate degree from Northwestern University School of Law and an MBA from Kellogg School of Management.

View full profile

Chart Merck & Co., Inc.

Duration

Period

MRK: Dynamic Chart

Company Profile

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (73.9%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (15.5%); - sale of animal health products (9.8%); - other (0.8%). Net sales are distributed geographically as follows: the United States (56.2%), Europe/Middle East/Africa (22.4%), Latin America (5.2%), Asia/Pacific (4.6%), Japan (4.2%), China (3%) and other (4.4%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

05-15 -

More about the company